Patent · US Active

Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

US8492381B2 · kind B2 · utility

41Cited by
14References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 14, 2011
Grant dateJul 23, 2013
Priority date—
Expiry dateNov 14, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D498/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are Heteroaryl Compounds having the following structure:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.